Clinical Trial Update: Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy [Phase 2]

View source ↗

Summary

Completed Phase 2 study evaluating neoadjuvant and adjuvant abiraterone acetate plus apalutamide in men with prostate cancer undergoing prostatectomy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• ERLEADA (apalutamide)
• Zytiga (abiraterone acetate)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED | Results posted: 2021-09-05